Prof. Quan-Yang Duh: the increasing morbidity of PTMC in America may be resulted from overtreatment
Meet the Professor

Prof. Quan-Yang Duh: the increasing morbidity of PTMC in America may be resulted from overtreatment


Received: 21 April 2017; Accepted: 05 May 2017; Published: 06 June 2017.

doi: 10.21037/aot.2017.05.03


The 2017 Annual Congress of International Society of Oncoplastic Endocrine Surgeons (ISOPES) was successfully held during April 20–23 in Hangzhou, China. Many renowned surgeons, abroad and at home attended this congress, presenting their personal clinical experience and sharing the state of art in endocrine surgery field.

During the congress, the editorial office of Annals of Thyroid (AOT) is honored to get a chance to interview Prof. Quan-Yang Duh from University of California, San Francisco, USA (Figure 1). According to Prof. Duh, there is a dramatically increasing morbidity of papillary thyroid microcarcinoma (PTMC) in the USA, which may be caused by the overtreatment. Currently we may do too much to the patients. When it came to early diagnosis, Prof. Duh said the problem was that we diagnosed the cancer too early and treat too early, as many small cancers didn’t actually grow to be clinical cancers. For the part of PTMC to be treated, surgery still plays a key role. While in the USA, which of the three non-traditional thyroid surgery, endoscopy, robot, and remote is more popular? Welcome to watch the video to get more Prof. Duh’s opinions (Figure 2).

Figure 1 Prof. Quan-Yang Duh and our Science Editor Molly Wang.
Figure 2 Prof. Quan-Yang Duh: the increasing morbidity of PTMC in America may be resulted from overtreatment (1). Available online: http://www.asvide.com/articles/1548

Interview questions

  • In your speech, you talked about PTMC in United States. What’s the morbidity of PTMC in United States?
  • Any possibility to early diagnose it?
  • Can you share with us the major treatments in United States?
  • Among the three non-traditional thyroid surgery, endoscopy, robot, and remote, which one is more popular in United States?
  • Is there any promising surgical treatment for thyroid cancer?

Expert introduction

Dr. Quan-Yang Duh is Professor and Chief of Endocrine Surgery and Associate Director of Advanced Videoscopic Surgery Center at UCSF. He is an attending surgeon at both UCSF Medical Center and San Francisco VA Medical Center. Dr. Duh specializes in surgery to treat tumors of the thyroid, parathyroid and adrenal glands, as well as endocrine and gastrointestinal malignancies. He is nationally and internationally recognized for his expertise in complex minimally invasive procedures including laparoscopic adrenalectomy, thyroidectomy, parathyroidectomy and hernia repair.

Dr. Duh graduated from Yale University, New Haven, CT, USA, with a BS in Molecular Biophysics and Biochemistry. He completed his surgical internship, residency and postdoctoral fellowship at the University of California, San Francisco, USA. He is the past president of the American Association of Endocrine Surgeons and the San Francisco Surgical Society, as well as president of the American College of Surgeons’ Northern California Chapter. Highly respected by his peers, Dr. Duh was named to the list of US News “America’s Top Doctors”, a distinction reserved for the top 1% of physicians in the nation for a given specialty.


Acknowledgements

None.


Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.


References

  1. Wang M. Prof. Quan-Yang Duh: the increasing morbidity of PTMC in America may be resulted from overtreatment. Asvide 2017;4:239. Available online: http://www.asvide.com/articles/1548

(Science Editor: Molly Wang, AOT, aot@amegroups.com)

doi: 10.21037/aot.2017.05.03
Cite this article as: Wang M. Prof. Quan-Yang Duh: the increasing morbidity of PTMC in America may be resulted from overtreatment. Ann Thyroid 2017;2:2.